home / stock / ocup / ocup news

OCUP News and Press, Ocuphire Pharma Inc Com From 01/04/24

Stock Information
Company Name: Ocuphire Pharma Inc Com
Stock Symbol: OCUP
Market: NASDAQ
Website: ocuphire.com
Menu
OCUP OCUP Quote OCUP Short OCUP News OCUP Articles OCUP Message Board
Get OCUP Alerts

News, Short Squeeze, Breakout and More Instantly...
OCUP - Ocuphire Pharma Receives FDA Agreement Under Special Protocol Assessment for LYNX-2 Phase 3 Trial of Phentolamine Ophthalmic Solution for the Treatment of Decreased Visual Acuity under Dim (mesopic) Light Conditions

FARMINGTON HILLS, Mich., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced it h...
OCUP - Ocuphire Pharma, Inc. (OCUP) Ocuphire Pharma Corporate Update Call (Transcript)

2023-12-05 13:30:27 ET Ocuphire Pharma, Inc. (OCUP) Corporate Update Call December 05, 2023 10:00 AM ET Company Participants Dr. George Magrath - Chief Executive Officer Michael Wood - LifeSci Advisors Charlie Hoffmann - SVP of Corporate Development Ronil Pat...

OCUP - Earnings week ahead: DocuSign, NIO, Broadcom, GameStop and more

2023-12-03 08:02:00 ET The first full week of December features several significant companies slated to announce their quarterly results. These earnings releases hold considerable implications for various sectors, including energy, software, retail, autos and semiconductors. Among the c...

OCUP - Ocuphire Pharma Announces Presentation at Ophthalmology Innovation Summit (OIS) XIII

FARMINGTON HILLS, Mich., Nov. 30, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced that...
OCUP - Ocuphire announces appointment of Joseph Schachle as chief operating officer

2023-11-27 09:32:24 ET More on Ocuphire Pharma Viatris and Ocuphire Pharma announce FDA approval for eye drop formulation RYZUMVl Seeking Alpha’s Quant Rating on Ocuphire Pharma Historical earnings data for Ocuphire Pharma Financial information for Ocu...

OCUP - Ocuphire Pharma Announces Appointment of Joseph Schachle, M.B.A., as Chief Operating Officer

FARMINGTON HILLS, Mich., Nov. 27, 2023 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing small-molecule therapies for the treatment of retinal and refractive eye disorders, today announced the ...

OCUP - Ocuphire Pharma GAAP EPS of $0.25, revenue of $11.94M

2023-11-13 14:30:41 ET More on Ocuphire Pharma Viatris and Ocuphire Pharma announce FDA approval for eye drop formulation RYZUMVl Seeking Alpha’s Quant Rating on Ocuphire Pharma Historical earnings data for Ocuphire Pharma Financial information for Ocu...
OCUP - Ocuphire Pharma Announces Financial Results for Third Quarter 2023 and Provides Corporate Update

Successful End-of-Phase 2 Meeting with FDA for Oral APX3330; Agreement on Phase 3 Registration Endpoint RYZUMVI ™ Approved by FDA; Ocuphire Received $10 million Regulatory Milestone Payment VEGA-2 Phase 3 Presbyopia Trial Met Primary Endpoint; Viatris Expected to Co...

OCUP - Expected US Company Earnings on Friday, November 10th, 2023

Yaskawa Electric Corporation ADR (YASKY) is expected to report for Q2 2024 Bank of China Ltd. ADR (BACHY) is expected to report for Q2 2024 Algonquin Power & Utilities Corp. (AQN) is expected to report $0.11 for Q3 2023 Soho House & Co Inc. Class A (SHCO) is expected to report...

OCUP - Expected US Company Earnings on Friday, November 3rd, 2023

HST Global Inc (HSTC) is expected to report for quarter end 2023-09-30 Air China Ltd ADR - Level I (AIRYY) is expected to report for Q3 2023 GrafTech International Ltd. (EAF) is expected to report $-0.05 for Q3 2023 Cardinal Health Inc. (CAH) is expected to report $1.4 for Q1 2024 ...
Previous 10 Next 10